Memory Studies

Join our Memory Study

Today Re:Cognition Health is recognized as the leading independent provider of Center services for cognitive disorders with successful award-winning business in:

  • Adult acquired and progressive neuro-degenerative diseases Traumatic Brain injury –including medicolegal witness reporting and rehabilitation
  • International Clinical Trials for Alzheimer’s Disease (AD) and other Central Nervous System (CNS) disorders.

Altoida

Detecting an MCI and Amyloid Digital Neuro Signature (DNS) using Altoida’s multimodal digital biomarkers. Ground Truth data collection.

To be eligible for this study, a potential participant must:

  • Male or female, 50+ years at the time of consent.
  • At least four years of formal education (from primary school onwards).
  • Adequate vision to complete the Altoida assessment and neuropsychological tests with or without corrective lenses.
  • Has Not been in a clinical trial longer than six months of any potential disease-modifying anti-amyloid AD treatment.
Register Now!

Aribio

A placebo-controlled study to evaluate the effects of AR1001 in participants with early AD(more advanced patients with mild to moderate AD).

To be eligible for this study, a potential participant must:

  • Be between the ages of 55 and 90
  • Have noticed a change in your memory for at least 3 years.
  • Study partner during the study
  • Be diagnosed with, or have a suspected clinical diagnosis of, Alzheimer’s disease/ Mild cognitive Impairment.
Register Now!

Gemvax

A placebo-controlled study to evaluate the effect, safety and Efficacy of GV1001 in participants with mild to moderate AD.

To be eligible for this study, a potential participant must:

  • Be between the ages of 55 and 85
  • Study partner during study
  • Mild to moderate Dementia
Register Now!

Prothena

This is a Multiple Ascending Dose Study to Evaluate the safety and tolerability of a drug called PRX012 in Subjects with Alzheimer’s Disease, when compared to a placebo. Joining our clinical trial is a valuable opportunity to contribute to the advancement of medical research while receiving compensation for your participation. Additionally, we may offer reimbursements for clinical trial-related travel expenses and do not require health insurance. Don’t miss out on the chance to make a meaningful impact on the future of healthcare.

To be eligible for this study, a potential participant must:

  • Be between the ages of 55 and 85
  • Have a confirmed or suspected diagnosis of mild Alzheimer’s disease or mild cognitive impairment due to Alzheimer’s disease
  • Have noticed gradual and progressive change in memory function for at least 6 months
  • Be willing and able to complete brain imaging (MRI and PET scans)
Register Now!

SAGE – Lightwave Study

This is a placebo-controlled study to evaluate the effects of SAGE-718 in participants with Mild Cognitive Impairment or Mild Dementia due to Alzheimer’s Disease. The primary objective of the LIGHTWAVE study is to determine if the cognitive enhancements observed during the two-week LUMINARY dosing period will be sustained over a longer duration. The study will specifically evaluate the effectiveness of the drug using the Digit Symbol Substitution test, a brief cognitive assessment that is highly responsive to changes in cognition and is believed to provide the most accurate reflection of daily cognitive abilities in patients.

To be eligible for this study, a potential participant must:

  • Be between the ages of 50 and 80
  • Have noticed a change in your memory
  • Have a family member or loved one who can be available as a study partner during the study
  • Be diagnosed with, or have a suspected clinical diagnosis of, Alzheimer’s disease – This is one of our more mild studies, so no diagnosis needed – as long as the patient has noticed significant concerns with their memory
Register Now!

Cognito

Be part of the development of a new device that has the potential to slow the progression of Alzheimer’s disease, from the comfort of home without medications or highly invasive procedures. The objective of this study is to assess the effect of gamma sensory stimulation in individuals with mild/moderate Alzheimer’s Disease on function, cognition and symptoms.

To be eligible for this study, a potential participant must:

  • Be between the ages of 50 and 85
  • Have noticed a change in your memory
  • Have a family member or loved one who can be available as a study partner during the study
Register Now!